Yao Xiaodan, Ajani Jaffer A, Song Shumei
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Transl Gastroenterol Hepatol. 2020 Oct 5;5:57. doi: 10.21037/tgh.2020.02.08. eCollection 2020.
Peritoneal metastases occur in 55-60% of patients with gastric cancer (GC) and are associated with a 2% 5-year overall survival rate. There are limited treatment options for these patients, and no targeted therapy or immunotherapy is available. Rational therapeutic targets remain to be found. In this review, we present the published literature and our own recent experience in molecular biology to identify important molecules and signaling pathways as well as cellular immunity involved in the peritoneal metastasis of GC. We also suggest potential novel strategies for improving the outcomes of GC patients with peritoneal metastasis.
55%-60%的胃癌（GC）患者会发生腹膜转移，其5年总生存率仅为2%。这些患者的治疗选择有限，且尚无靶向治疗或免疫治疗方法。合理的治疗靶点仍有待发现。在本综述中，我们展示了已发表的文献以及我们自己在分子生物学方面的最新经验，以确定参与GC腹膜转移的重要分子、信号通路以及细胞免疫。我们还提出了改善GC腹膜转移患者预后的潜在新策略。
